Navigation Links
Major HIV prevention trial in women to drop oral tenofovir arm
Date:9/28/2011

erns, and the DSMB recommended each time that the study continue, without changes. The next routine review of VOICE data by the DSMB will take place in mid-November of this year. This will be the sixth routine review and the third interim efficacy analysis of VOICE.

Globally, women account for 60 percent of adults with HIV in sub-Saharan Africa, where unprotected heterosexual intercourse is the primary driver of the epidemic. Young women are especially vulnerable. In southern Africa, young women are up to five times more likely to become infected with HIV than young men, and more than a quarter (26 percent) of all new global HIV infections occur in women aged 15-24. Women are twice as likely as their male partners to acquire HIV during sex. Although correct and consistent use of male condoms has been shown to prevent HIV, women are not always able to negotiate their use. Women desperately need methods for preventing HIV that they can control themselves. ARV-based prevention methods as either a vaginal gel or an oral tablet are promising approaches.

Oral tenofovir (tenofovir disoproxil fumarate), known by the brand name Viread , and Truvada, a combination tablet that contains tenofovir and emtricitabine, are both approved for the treatment of HIV when used in combination with other ARVs. Viread and Truvada are registered trademarks of Gilead Sciences, Inc., of Foster City, Calif., U.S. Both have been evaluated in clinical trials in different at-risk populations to determine if they can prevent HIV in people who are HIV-negative. Besides VOICE, only one other PrEP effectiveness trial is currently ongoing. The U.S. Centers for Disease Control and Prevention is testing the effectiveness of oral tenofovir taken daily for reducing the risk of HIV among 2,400 injection drug users in Thailand. Results are anticipated in 2012.

Tenofovir gel is a vaginal microbicide that contains the same active ingredient as the oral tablet formulation of tenofo
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-916-3315
Microbicide Trials Network
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. One Month after Major Quake, Ongoing Crises for Haitian Children
2. Virginia House Majority Leader Morgan Griffith Sponsors Legislation Enabling Mobile Solution for Health Care SALEM, Va.
3. Major milestone achieved by our joint venture in China
4. Sunquest Announces Major Software Updates and Enhancements
5. MIT China joint venture is preparing a major commercial launch in July 2010
6. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
7. Highlights of major physics conference in Washington, D.C.
8. The Icebox of Atlanta Selected as T-shirt Vendor for 3 Major Divisions of American Cancer Society's Relay For Life
9. Majority of Marylanders without advance medical directives
10. Pew Report Finds Majority of States Fail to Ensure Proper Dental Health & Access to Care for Children
11. Americans Remain Split on Stalled Health Care Legislation, but Some Provisions Popular Among Majorities of Democrats, Independents and Republicans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Drugs,(NYSE: LDG ) announced its flu immunization program at ... of those communities remain,healthy and combat the annual flu season. ... meet its customers, needs. -- Longs Drugs will be ... beginning in October through the middle of November. ...
... for Trading on OTC Bulletin Board Shortly -, ... Board: EMED) announced today that the U.S. Securities and,Exchange ... by Card Activation Technologies, Inc. As a result of,the ... its Form 211 application, as filed with the NASD, ...
... 24 With the cold and,flu season now upon ... to washing their hands on a regular basis because,according ... hands is,the single most important measure people can take ... "Studies have shown that 40 percent of women and ...
... Cancer Center at Jefferson and Thomas Jefferson University Hospital ... implant radiation-emitting seeds in prostate cancer patients. While the ... based in The Netherlands, is only being used for ... help with the actual placement of the seeds. To ...
... Hope",charity auction, hosted by Pittsburgh Steeler Alan Faneca and his ... - 11 p.m. at the Jerome,Bettis Grille 36 on the ... the evening off with an autograph session from 7-8,p.m. Throughout ... of sports,memorabilia will take place. Local sportscaster Bob Pompeani will ...
... PRINCETON, N.J., Sept. 23 Covance Inc. (NYSE:,CVD) today ... Life Sciences,Conference on September 24 at 3:30 pm ET. ... http://www.covance.com . In order to register and,download any ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine News:Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:MedCom USA's Subsidiary Card Activation Technologies, Inc.'s SB2 Registration Declared Effective by SEC 2Health News:Clean Hands are Key to Fighting Cold, Flu Germs 2Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Super Bowl Champion, Pro Bowler and Pittsburgh Steeler Alan Faneca to Host Sixth Annual 'Bid for Hope' Auction 2
(Date:5/17/2013)...  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... UBS Global Healthcare Conference in New York ... at 11 a.m. Eastern Time. To listen to the ... the Investor Relations section of the Company,s Web site at ... days after the event. About Orexigen® Therapeutics ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... PLYMOUTH MEETING, Pa., June 9 Genaera,Corporation ... presentation by Genaera,scientists of preclinical data on ... treatment of type 2 diabetes and obesity, ... Diabetes Association in San,Francisco, California., The ...
... SUNNYVALE, Calif., June 9 Pharmacyclics, Inc.,(Nasdaq: ... study evaluating,PCI-32765, an orally available, selective inhibitor of ... an established animal model,for rheumatoid arthritis (RA). The ... Societies (FOCIS) meeting being held this,week in Boston, ...
Cached Medicine Technology:Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 2Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 3Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 4Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: